Literature DB >> 32474850

Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study.

Frédéric Lapostolle1, Elodie Schneider2, Isabelle Vianu2, Guillaume Dollet2, Bastien Roche2, Julia Berdah2, Julie Michel2, Laurent Goix2, Erick Chanzy2, Tomislav Petrovic2, Frédéric Adnet2.   

Abstract

Clinical features of COVID-19 have been mostly described in hospitalized patients with and without ICU admission. Yet, up to 80% of patients are managed in an outpatient setting. This population is poorly documented. In France, health authorities recommend outpatient management of patients presenting mild-to-moderate COVID-19 symptoms. The aim of this study was to describe their clinical characteristics. The study took place in an emergency medical dispatching center located in the Greater Paris region. Patients included in this survey met confirmed COVID-19 infection criteria according to the WHO definition. We investigated clinical features and classified symptoms as general, digestive, ear-nose-throat, thoracic symptoms, and eye disease. Patients were included between March 24 and April 6 2020. 1487 patients included: 700 (47%) males and 752 (51%) females, with a median age of 44 (32-57) years. In addition to dry cough and fever reported in more than 90% of cases, the most common symptoms were general symptoms: body aches/myalgia (N = 845; 57%), headache (N = 824; 55%), and asthenia (N = 886; 60%); shortness of breath (N = 479; 32%) and ear-nose-throat symptoms such as anosmia (N = 415; 28%) and ageusia (N = 422; 28%). Chest pain was reported in 320 (21%) cases and hemoptysis in 41 (3%) cases. The main difference between male and female patients was an increased prevalence of ear-nose-throat symptoms as well as diarrhea, chest pains, and headaches in female patients. General symptoms and ear-nose-throat symptoms were predominant in COVID-19 patients presenting mild-to-moderate symptoms. Shortness of breath and chest pain were remarkably frequent.

Entities:  

Keywords:  COVID-19; Clinical feature; Epidemic; Out-patient

Mesh:

Year:  2020        PMID: 32474850      PMCID: PMC7260461          DOI: 10.1007/s11739-020-02379-z

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


Introduction

Many papers have described the COVID-19 patient population [1, 2]. The majority have reported clinical features in hospitalized with or without ICU admission, mostly in China and more recently in Italy [3, 4]. Yet, most of the patients in these countries were managed in an outpatient setting. This population has been excluded of the studies and its characteristics are poorly documented. In France, health authorities were quick to recommend outpatient management of patients with suspected or confirmed COVID-19 infection who presented with mild-to-moderate symptoms. Patients were asked to contact the emergency medical system (SAMU) with their questions and in the event of worsening symptoms. SAMU can be reached with a single national toll-free number, nationwide, ‘15’ [5]. Since the beginning of the epidemic in Europe at the end of February, the number of calls increased dramatically, up to 400% of normal call volume. After an initial assessment by an EMS regulator, patients with less severe symptoms were not immediately connected to the emergency physician dispatcher, but received a follow-up telephone call within the following 12 h. This is the patient cohort studied here. The aim of this study was to describe the clinical characteristics of a large cohort of COVID-confirmed patients managed in outpatient settings, and to compare this clinical feature with previously published features.

Methods

Site

The study took place in SAMU 93 emergency medical dispatching center located in the Seine-Saint-Denis district of the Greater Paris, north-east of Paris proper. This district encompasses a population of 1.6 million for an area of 236 km2, making it one of the most densely populated districts in France; it is also the most socioeconomically disadvantaged district. Our call center received 750,000 calls in 2019, resulting in the management of 250,000 patients.

Procedure

During the study period, patients were included in our prospective observational survey if they met confirmed COVID-19 infection criteria according to the WHO definition, i.e., positive PCR or fever (during the last 48 h) and dry cough (https://www.who.int). We investigated clinical features and classified symptoms as general symptoms (body aches/myalgia, headache, and asthenia), digestive symptoms (anorexia, nausea, vomiting, and diarrhea), ear–nose–throat symptoms (pharyngalgia, rhinopharyngitis, anosmia and ageusia), respiratory and chest symptoms (shortness of breath, chest pain, and hemoptysis), and eye disease. Finally, the decision whether or not to transfer the patient to the hospital was recorded. As patients were asked to call back the SAMU in case of worsening symptoms, only the first call was considered an inclusion criterion. Patients were included between March 24 and April 6.

Analysis and ethics

Our primary aim was to compare clinical features of COVID-19 infection in male and female patients. We also compared clinical features based on the main inclusion criteria, positive PCR vs clinically confirmed COVID-19. The aim was to include 1500 consecutive patients. The management of the patients was not affected by the study. According to French law, the study was recorded at the Commission Nationale Informatique et Liberté (CNIL 1881609), the French national data protection authority. Qualitative date was compared using a Chi-square test; quantitative date was compared using a Student T test. A p value < 0.05 was considered as significant. Results are expressed as N (%) or median (IQ). Statistical analysis was performed using R 3.6.3.

Results

During the study period, 5104 patients were screened as having no signs of severity and 1487 (29%) were included: 700 (47%) patients were male and 752 (51%) were female (missing data: N = 35) with a median age of 44 (32–57) years. Among these patients, 28 (2%) were aged under 16 years and 12 (1%) under 10. COVID-19 infection was diagnosed according to clinical symptoms (fever + cough) in 1351 (91%) cases and according to PCR test in 197 (13%) cases. In addition to dry cough and fever (inclusion criteria) reported in more than 90% of cases, the most common symptoms were general symptoms: body aches/myalgia (N = 845; 57%), headache (N = 824; 55%), asthenia (N = 886; 60%); ear–nose–throat symptoms such as anosmia (N = 415; 28%), ageusia (N = 422; 28%), ageusia and anosmia (N = 335; 23%), and shortness of breath (N = 479; 32%). Chest pain was reported in 320 (22%) cases and hemoptysis in 41 (3%) cases. Complete results are reported in Fig. 1. The main difference between male and female patients was the prevalence of ear–nose–throat symptoms (Table 1). Chest pain and headaches were also more frequent in female patients.
Fig. 1

Symptom prevalence in a cohort of COVID-19 patients managed in outpatient settings (N = 1487). Results are presented by rate with a 95% confidence interval

Table 1

Comparison of symptom prevalence between male and female patients in a cohort of COVID-19 patients managed in outpatient settings (N = 1487)

MaleFemalep
N700 (48%)752 (52%)
Age (years)44 [32–57]41 [30–54]0.3
Inclusion criteria
 COVID-confirmed81 (11%)109 (14%)0.1
 Dry cough661 (94%)707 (94%)0.8
 Fever658 (94%)686 (91%)0.06
General symptoms
 Ache/myalgia379 (54%)444 (59%)0.07
 Headache341 (49%)462 (61%) < 0.0001
 Asthenia430 (61%)434 (58%)0.2
Digestive symptoms
 Anorexia156 (22%)149 (20%)0.3
 Nausea122 (17%)166 (22%)0.03
 Vomiting75 (11%)93 (12%)0.4
 Diarrhea153 (22%)199 (26%)0.047
Ear–nose–throat symptoms
 Pharyngalgia159 (23%)218 (29%)0.008
 Rhinopharyngitis85 (12%)122 (16%)0.03
 Anosmia169 (24%)237 (32%)0.002
 Ageusia176 (25%)238 (32%)0.007
Respiratory and chest symptoms
 Shortness of breath213 (30%)250 (33%)0.3
 Chest pain127 (18%)181 (24%)0.007
 Hemoptysis22 (3%)17 (3%)0.4
 Eye disease24 (3%)38 (5%)0.2
 Transfer hospital35 (5%)44 (6%)0.6

Results are presented as N (%) or [IQ]

After assessment by phone, 83 (6%) patients were transferred to the hospital, without significant difference in terms of gender. Symptom prevalence in a cohort of COVID-19 patients managed in outpatient settings (N = 1487). Results are presented by rate with a 95% confidence interval Comparison of symptom prevalence between male and female patients in a cohort of COVID-19 patients managed in outpatient settings (N = 1487) Results are presented as N (%) or [IQ] Results of the comparison between clinical features in patients with positive PCR and those with clinically confirmed COVID-19 are reported in the Supplementary Annexes. Patients with positive PCR were younger and complained less frequently of body aches and asthenia and more frequently of vomiting and shortness of breath.

Discussion

The clinical features of COVID-19 infection in this large cohort of patients managed in outpatient settings were extremely varied. As previously reported, general symptoms, i.e., flu-like symptoms such as fever, cough, and asthenia, and body aches and headaches were the most frequent symptoms. Female patients were more likely to present ear–nose–throat symptoms, chest pain, and headaches than male patients. Our first aim was to describe the symptoms observed in patients who received outpatient care. We were able to complete this goal, as only 5% of patients were transferred to the hospital after medical evaluation by the emergency physician dispatcher. As 80% of COVID-19 patients worldwide are managed in outpatient settings, we postulate that the clinical features described here apply to most COVID-19 patients. Consequently, in our study, sex ratio is close to the global population. It contrasts with the in-hospital patient population which is predominantly male in ICU and other hospital departments [4, 6–8]. Anosmia and ageusia have become cardinal signs of COVID-19, but these symptoms were under-reported in the first papers from China. Its prevalence was higher in our findings than previously reported in Chinese and Italian papers, which report these symptoms in 5–6% and 19% of cases, respectively [9, 10]. These symptoms appear to be more prevalent in patients presenting mild-to-moderate symptoms [11]. The physiopathology of anosmia and ageusia is still unclear. As this symptom is infrequent in clinical practice, it should be considered a sensitive diagnostic criterion [10]. A few recent papers have described the clinical features of mild-to-moderate COVID-19 in hospitalized patients [12-14]. General symptoms such as anosmia, asthenia, headaches, and myalgia were the most frequently reported symptoms. A score based on these symptoms has been proposed [13]. Chest pain was frequent, occurring in 20% of cases, and can be explained by pulmonary disease and severe coughing. However, specific injuries such as pericarditis and myocarditis as well as pulmonary embolism have been found [15-17]. Cardiovascular complications seem to be largely involved in critical outcome [18]. Nevertheless, we currently are unsure of the relevance of investigating chest pain with electrocardiogram and echocardiography in paucisymptomatic patients. Moreover, due to the high prevalence of chest pain, it was unrealistic to propose systematic investigations. Hemoptysis was not uncommon. Recent emergency medicine papers on pulmonary embolisms, which is the most frequent cause of hemoptysis in emergency medicine, reveal that hemoptysis occurred in 2–8% of pulmonary embolisms [19, 20].

Limitations

The main limit of this study is the lack of definitive COVID infection confirmation by RT-PCR. However, we based ourselves on the WHO’s inclusion criteria. The second limit is the lack of clinical assessment. Symptoms were reported by patients and not directly recorded by a physician. Due to the overload of the emergency medical system, we opted to employ this more realistic strategy. For this reason, we decided to manage these patients at home, in an outpatient setting. The third limit is the lack of follow-up. For similar reasons, this was not feasible.

Conclusion

In this original and large cohort of confirmed COVID-19 patient population managed in outpatient settings in the greater Paris area, symptoms were different from those previously reported. Digestive and ear–nose–throat symptoms were frequent. Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 21 kb)
  19 in total

1.  Sixty seconds on . . . anosmia.

Authors:  Gareth Iacobucci
Journal:  BMJ       Date:  2020-03-24

Review 2.  Mild or Moderate Covid-19.

Authors:  Rajesh T Gandhi; John B Lynch; Carlos Del Rio
Journal:  N Engl J Med       Date:  2020-04-24       Impact factor: 91.245

3.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

4.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.

Authors:  Giacomo Grasselli; Alberto Zangrillo; Alberto Zanella; Massimo Antonelli; Luca Cabrini; Antonio Castelli; Danilo Cereda; Antonio Coluccello; Giuseppe Foti; Roberto Fumagalli; Giorgio Iotti; Nicola Latronico; Luca Lorini; Stefano Merler; Giuseppe Natalini; Alessandra Piatti; Marco Vito Ranieri; Anna Mara Scandroglio; Enrico Storti; Maurizio Cecconi; Antonio Pesenti
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

5.  COVID-19 and the Heart.

Authors:  Akbarshakh Akhmerov; Eduardo Marbán
Journal:  Circ Res       Date:  2020-04-07       Impact factor: 17.367

6.  Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia.

Authors:  Rui Han; Lu Huang; Hong Jiang; Jin Dong; Hongfen Peng; Dongyou Zhang
Journal:  AJR Am J Roentgenol       Date:  2020-03-17       Impact factor: 3.959

7.  COVID-19: towards controlling of a pandemic.

Authors:  Juliet Bedford; Delia Enria; Johan Giesecke; David L Heymann; Chikwe Ihekweazu; Gary Kobinger; H Clifford Lane; Ziad Memish; Myoung-Don Oh; Amadou Alpha Sall; Anne Schuchat; Kumnuan Ungchusak; Lothar H Wieler
Journal:  Lancet       Date:  2020-03-17       Impact factor: 79.321

8.  Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020.

Authors:  Alma Tostmann; John Bradley; Teun Bousema; Wing-Kee Yiek; Minke Holwerda; Chantal Bleeker-Rovers; Jaap Ten Oever; Corianne Meijer; Janette Rahamat-Langendoen; Joost Hopman; Nannet van der Geest-Blankert; Heiman Wertheim
Journal:  Euro Surveill       Date:  2020-04

9.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

10.  Anosmia and Ageusia: Common Findings in COVID-19 Patients.

Authors:  Luigi A Vaira; Giovanni Salzano; Giovanna Deiana; Giacomo De Riu
Journal:  Laryngoscope       Date:  2020-04-15       Impact factor: 3.325

View more
  39 in total

1.  Taste loss as a distinct symptom of COVID-19: a systematic review and meta-analysis.

Authors:  Mackenzie E Hannum; Riley J Koch; Vicente A Ramirez; Sarah S Marks; Aurora K Toskala; Riley D Herriman; Cailu Lin; Paule V Joseph; Danielle R Reed
Journal:  Chem Senses       Date:  2022-01-01       Impact factor: 3.160

2.  Risk factors and outcome of COVID-19 in patients with hematological malignancies.

Authors:  José Luis Piñana; Rodrigo Martino; Irene García-García; Rocío Parody; María Dolores Morales; Gonzalo Benzo; Irene Gómez-Catalan; Rosa Coll; Ignacio De La Fuente; Alejandro Luna; Beatriz Merchán; Anabelle Chinea; Dunia de Miguel; Ana Serrano; Carmen Pérez; Carola Diaz; José Luis Lopez; Adolfo Jesús Saez; Rebeca Bailen; Teresa Zudaire; Diana Martínez; Manuel Jurado; María Calbacho; Lourdes Vázquez; Irene Garcia-Cadenas; Laura Fox; Ana I Pimentel; Guiomar Bautista; Agustin Nieto; Pascual Fernandez; Juan Carlos Vallejo; Carlos Solano; Marta Valero; Ildefonso Espigado; Raquel Saldaña; Luisa Sisinni; Josep Maria Ribera; Maria Jose Jimenez; Maria Trabazo; Marta Gonzalez-Vicent; Noemí Fernández; Carme Talarn; Maria Carmen Montoya; Angel Cedillo; Anna Sureda
Journal:  Exp Hematol Oncol       Date:  2020-08-25

3.  Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis.

Authors:  P Brito-Zerón; B Gracia-Tello; A Robles; A Alguacil; M Bonet; B De-Escalante; A Noblejas-Mosso; R Gómez-de-la-Torre; M Akasbi; M Pérez-de-Lis; R Pérez-Alvarez; M Ramos-Casals
Journal:  Viruses       Date:  2021-05-27       Impact factor: 5.048

Review 4.  COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era.

Authors:  Arens Taga; Giuseppe Lauria
Journal:  J Peripher Nerv Syst       Date:  2022-03-14       Impact factor: 5.188

5.  Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England.

Authors:  Colin S Brown; Kathryn Clare; Meera Chand; Julie Andrews; Cressida Auckland; Sarah Beshir; Saher Choudhry; Kerrie Davies; Jane Freeman; Andrew Gallini; Rachel Moores; Trupti Patel; Gosia Poznalska; Alison Rodger; Stella Roberts; Christopher Rooney; Mark Wilcox; Simon Warren; Joanna Ellis; Robin Gopal; Jake Dunning; Maria Zambon; Susan Hopkins
Journal:  J Infect       Date:  2020-06-30       Impact factor: 6.072

6.  Mortality and other outcomes of patients with coronavirus disease pneumonia admitted to the emergency department: A prospective observational Brazilian study.

Authors:  Rodrigo A Brandão Neto; Julio F Marchini; Lucas O Marino; Julio C G Alencar; Felippe Lazar Neto; Sabrina Ribeiro; Fernando V Salvetti; Hassan Rahhal; Luz Marina Gomez Gomez; Caue G Bueno; Carine C Faria; Victor P da Cunha; Eduardo Padrão; Irineu T Velasco; Heraldo Possolo de Souza
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

7.  Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia.

Authors:  Pedro Augusto Sampaio Rocha-Filho; João Eudes Magalhães
Journal:  Cephalalgia       Date:  2020-11       Impact factor: 6.292

8.  A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort Study.

Authors:  Hossein Kasiri; Cyrus Mahjub; Mohammadreza Mazaeri; Fahimeh Naderi-Behdani; Aliyeh Bazi; Monireh Ghazaeian; Sahar Fallah
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-07-20       Impact factor: 2.471

9.  Mild to moderate COVID-19 illness in adult outpatients: Characteristics, symptoms, and outcomes in the first 4 weeks of illness.

Authors:  Janis E Blair; Ashwini Gotimukul; Fangfang Wang; Syeda A Mina; Helen C Bartels; Mark W Burns; Amy E Kole; Holenarasipur R Vikram; Juan C Gea-Banacloche; M Teresa Seville; Skye A Buckner Petty; Avinash Vikram; Robert Orenstein
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

10.  "COVID-19: diagnosis, management and prognosis": a new topical collection of Internal and Emergency Medicine.

Authors:  Riccardo Polosa; Michele Spinicci; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2020-07-30       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.